Journal of Neuro-Oncology最新文献

{"title":"Surgical outcomes in octogenarian meningioma patients: a multicenter retrospective analysis of frailty and radiological predictors : Frailty in octogenarians undergoing meningioma resection.","authors":"Pedro David Delgado-López, Antonio Montalvo-Afonso, Roberto García-Leal, Sergio Martín-García, Alfonso Lagares, Ana María Castaño León, Miguel Gelabert-González, Eduardo Arán-Echabe, Carlos A Rodríguez-Arias, Salim Khayat, José F Alén, Amelia Álvarez-Sala, Rosario Sarabia, Olga Esteban Sinovas, Luis Torres Carretero, Angela Dayana Tapia Moscoso, Victor Rodríguez-Domínguez, Alberto Isla Guerrero, Javier Robla Costales, David Santamarta Gómez, Vicente Martín-Velasco, Javier Martín Alonso, Ane Barreras García, Rubén Diana Martín, Eva María Corrales-García","doi":"10.1007/s11060-025-05174-y","DOIUrl":"https://doi.org/10.1007/s11060-025-05174-y","url":null,"abstract":"<p><strong>Background: </strong>The rising life expectancy has led to an increased incidence of meningiomas among the elderly. In octogenarians, surgical decision-making remains particularly challenging due to frailty, comorbidities, and the risk of postoperative decline. This study investigates whether preoperative frailty indices and radiological features predict surgical outcomes in this high-risk population.</p><p><strong>Methods: </strong>A multicenter retrospective cohort study was conducted across ten Spanish tertiary care centers, including 189 patients aged ≥ 80 years who underwent intracranial meningioma resection between 2010 and 2023. Preoperative variables included the 5-item Frailty Index (5-FI), Charlson Comorbidity Index (CCI), American Society of Anesthesiologists (ASA) classification, and tumor-specific imaging characteristics (tumor diameter, peritumoral edema, and venous sinus involvement). The primary endpoint was the occurrence of Unfavorable Outcome (any postoperative neurological deficit, 30-day mortality, or major complication). Secondary endpoints included variation of KPS score at 1 year, discharge disposition, and 1-year mortality. Both univariate and multivariate logistic regression models were applied.</p><p><strong>Results: </strong>Mean patient age was 83.0 ± 2.6 years, with 58.2% females. In univariate analysis, preoperative KPS < 70, higher WHO grade, and larger tumor diameter were associated with an unfavorable outcome. However, multivariate analysis identified only preoperative KPS < 70 as an independent predictor of worse outcome (OR 3.10, 95% CI 1.44-6.68, p = 0.004). At 12 months, functional status declined significantly (mean KPS from 73.5 to 63.5; p < 0.001), although 27.1% of patients remained functionally independent. New neurological deficits occurred in 23.8%, postoperative complications in 42.8%, and 30-day mortality was 4.2%. One-year mortality reached 15.8%. Predictors of 12-month KPS < 70 included higher age, preoperative KPS < 70, higher 5-FI, higher ASA grade, higher WHO grade, and the presence of major postoperative complications or new neurological deficits. In multivariate analysis, preoperative KPS < 70 (OR 14.45, 95% CI 5.64-37.03, p < 0.001) and the occurrence of new neurological deficits (OR 4.79, 95% CI 1.59-14.38, p = 0.005) were independent predictors of 12-month KPS < 70.</p><p><strong>Conclusions: </strong>In octogenarians undergoing meningioma surgery, frailty indices-especially low preoperative KPS-and tumor-related characteristics are stronger predictors of surgical outcomes than age alone. Incorporating individualized assessments of physiological reserve and tumor burden may improve surgical planning and preoperative counseling in this growing patient population.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the therapeutic effect on tumor cells through wireless optoelectronic stimulation.","authors":"E Iusupovskaia, N Isaev, A Antonian, A K Boromangnaeva, E Kuzmin, G Piavchenko, A Konovalov, G Pavlova, N Samoylenkova, P Timashev, D Telyshev, I Ulasov, Aleksandr Markov","doi":"10.1007/s11060-025-05171-1","DOIUrl":"https://doi.org/10.1007/s11060-025-05171-1","url":null,"abstract":"<p><strong>Purpose: </strong>Drug resistance is a major challenge in the treatment of tumor diseases, especially in glioblastoma (GBM), where temozolomide (TMZ) plays a critical role. However, the development of resistance to TMZ occurs rapidly in more than half of the patients who initially respond to the drug. This highlights the need for novel approaches to overcome drug resistance and improve therapeutic outcomes in GBM treatment.</p><p><strong>Methods: </strong>In our study, we combine TMZ treatment with wireless optoelectronics using advanced multilayered organic semiconductor (MOS) devices. These devices consist of a 200 nm thick stack of metal and p-n semiconducting organic nanocrystals. When illuminated in physiological solutions, these MOS devices charge up and convert light pulses into localized displacement currents, which are strong enough to electrically stimulate tumor cells at safe light intensities. Importantly, the freestanding MOS devices require no external wiring or bias and remain stable under physiological conditions. The semiconductor layers are created from common, non-toxic pigments using simple, scalable deposition methods.</p><p><strong>Results: </strong>Our results demonstrate that this combination of TMZ and optoelectronic stimulation significantly enhances apoptosis in tumor cells, thereby improving the effectiveness of TMZ in treating glioblastoma.</p><p><strong>Conclusion: </strong>his research suggests that the integration of wireless optoelectronic stimulation with TMZ treatment offers a promising strategy to overcome drug resistance in GBM. The use of MOS devices enhances the therapeutic effect of TMZ and could lead to better treatment outcomes for patients with glioblastoma.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends in cell-based therapies: contemporary advances and ethical considerations in translational neurosurgical oncology.","authors":"Matthew Abikenari, Justin Liu, Joseph H Ha, Shreyas Annagiri, Vratko Himic, Ravi Medikonda, Lily Kim, John Choi, Michael Lim","doi":"10.1007/s11060-025-05170-2","DOIUrl":"https://doi.org/10.1007/s11060-025-05170-2","url":null,"abstract":"<p><p>Emerging cell-based therapies represent a promising advancement in neurosurgical oncology, offering novel therapeutic possibilities for challenging diagnoses such as high-grade gliomas. Traditional treatment modalities, including surgical resection, chemotherapy, and radiotherapy, offer limited efficacy due to the highly infiltrative nature and genomic heterogeneity of malignant brain tumors. The recent integration of molecular profiling and genotypic characterization into diagnostic and therapeutic frameworks underscores a significant evolution toward personalized medicine. Stem-cell-based approaches, notably neural and mesenchymal stem cells, demonstrate remarkable tropism for pathological tissues, providing innovative strategies for targeted therapeutic delivery and intrinsic anti-tumoral effects. Concurrently, immunotherapeutic advancements, particularly immune checkpoint inhibitors (ICIs), chimeric antigen receptor T-cell (CAR T-cell) therapies, and tumor vaccination techniques, have significantly altered therapeutic paradigms by leveraging patient-specific immune responses with minimal systemic toxicity. To contextualize such therapeutic innovations, we systematically reviewed and analyzed 28 ongoing glioblastoma clinical trials initiated since 2022 investigating cell-based strategies. This dataset elucidates key patterns in trial design, cellular targets, and combinatorial immunotherapeutic regimens. Despite the immense clinical promise, integrating cell-based and immunological therapeutics necessitates careful ethical deliberation and complex clinical management strategies, particularly when combined with conventional therapies. This review critically evaluates contemporary advancements, highlights emerging clinical trial outcomes, explores the ethical dimensions of novel therapeutics, and underscores the imperative for continued translational research to refine patient-specific therapeutic paradigms in neurosurgical oncology.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic radiosurgery for recurrent high-grade gliomas: a systematic review.","authors":"Trent Kite, Bryce Bossinger, Vineetha Yadlapalli, Stephen Jaffee, John Herbst, Stephen Karlovits, Rodney E Wegner, Matthew J Shepard","doi":"10.1007/s11060-025-05156-0","DOIUrl":"https://doi.org/10.1007/s11060-025-05156-0","url":null,"abstract":"<p><strong>Purpose: </strong>Management of recurrent high-grade glioma (rHGG) is challenging. Contemporary therapeutic approaches include systemic chemotherapy, resection, conventional radiation, and stereotactic radiosurgery (SRS). Stereotactic radiosurgery is increasingly utilized given its low toxicity rates and relative efficacy. As the pace of research on this topic is rapidly evolving, a comprehensive review of the existing literature is necessary.</p><p><strong>Methods: </strong>A systematic review in accordance with the preferred reporting in systematic review and meta-analysis guidelines (PRISMA) was conducted. PubMed and Science Direct databases were queried for articles which reported a primary analysis on a cohort of patients with recurrent gliomas (WHO grade III and IV) treated with SRS. Articles meeting the inclusion criteria and satisfying the quality threshold were included in the final review.</p><p><strong>Results: </strong>In total 22 articles representing 1,191 patients satisfied the inclusion criteria and quality threshold. The articles spanned a time frame from 1999 to March 2025. Tumor subtypes were distributed as 245 (20.6%) grade III and 946 (79.4%) grade IV. Linear accelerator (LINAC) based SRS was the most frequently utilized SRS platform treating a median tumor volume of 9.9cm³ (range: 1.21-44.0) with a median prescription dose of 16.5 Gy. At one-year, the pooled actuarial survival was 53%. At the time of last radiographic follow up, the pooled local progression and distant progression were 58% and 35% respectively. Grade ≥ 3 toxicity ranged from 0 to 14%.</p><p><strong>Conclusions: </strong>For patients undergoing SRS for rHGG, overall survival times are consistent with alternative salvage therapies (chemotherapy, resection, and conventional radiotherapy) with relatively low treatment-related toxicity. Certain factors such as age, Karnofsky performance status (KPS), WHO grade, and interval between primary tumor treatment and reccurence/salvage SRS may be important in predicting treatment response.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024.","authors":"Megan Parker, Kelly Jiang, Anita Kalluri, Alyssa G Arbuiso, Austin Carmichael, Joshua Materi, Tej D Azad, Jinny Suk Ha, Solmaz Sahebjam, David O Kamson, Kristin J Redmond, Lawrence R Kleinberg, Xiaobu Ye, Chetan Bettegowda, Jordina Rincon-Torroella","doi":"10.1007/s11060-025-05139-1","DOIUrl":"https://doi.org/10.1007/s11060-025-05139-1","url":null,"abstract":"<p><strong>Purpose: </strong>Brain metastases (BM) cause substantial morbidity and mortality in patients with non-small cell lung cancer (NSCLC). Updated epidemiological studies are crucial to guide screening and treatment strategies. We investigated the prevalence, timing, and outcomes of BM in patients diagnosed with NSCLC utilizing the TrinetX Oncology database.</p><p><strong>Methods: </strong>Data from patients with histologically confirmed NSCLC were extracted from the TrinetX Oncology database. Precocious, synchronous, and metachronous BM were defined as BM diagnosed before, within 2 months, and after 2 months of the NSCLC diagnosis, respectively. Clinical variables were compared between patients with and without BM using Chi-squared and t-tests. Kaplan-Meier and Cox regression analyses were used to evaluate overall survival (OS), after propensity-score matching for age at diagnosis of NSCLC, sex, stage at diagnosis, extracranial metastases, and cancer-directed therapy.</p><p><strong>Results: </strong>Among 25,714 patients with NSCLC, 18.9% had BM (3.1% precocious, 6.5% synchronous, and 9.3% metachronous). The median time to BM was 7.7 months in patients with initial stage IV NSCLC. Patients with BM received significantly higher rates of cancer-directed therapies compared to those without BM. Patients with BM (with or without extracranial metastases) had reduced OS compared to patients with extracranial metastases only (HR[95%CI] = 1.2[1.1-1.3]). Synchronous BM were associated with lower OS than metachronous BM after the diagnosis of NSCLC (HR[95%CI] = 1.8[1.6-2.0]), but not after BM diagnosis.</p><p><strong>Conclusion: </strong>BM impact outcomes of patients with NSCLC causing significant morbidity and mortality. Our findings highlight the importance of early detection and targeted interventions in NSCLC patients at risk of BM.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tunneling nanotubes between glioblastoma cells and T cells and hijack of mitochondria.","authors":"Yanamandra Venkataratnam, Victor Mukherjee, Nikhil Rai, Mahesh Mahalingaswamy, Diksha Shandilya, Subhas Konar, Nandeesh Bevinahalli Nanjegowda, Girish Waghmare, Nandakumar Dalavaikodihalli Nanjaiah","doi":"10.1007/s11060-025-05150-6","DOIUrl":"https://doi.org/10.1007/s11060-025-05150-6","url":null,"abstract":"<p><strong>Purpose: </strong>Glioblastoma is a highly aggressive and invasive brain tumor that can interact dynamically with its surrounding tumor microenvironment, including resident and infiltrating-immune cells. These interactions largely govern glioblastoma progression and resistance to therapy. Glioblastoma cells can actively modulate immune cell functions, either by inhibiting immune responses or reprogramming immune cells. This study explores the dynamic interaction between glioblastoma cells and T cells.</p><p><strong>Methods: </strong>The connections between glioblastoma cells and T cells were analyzed by immunohistochemistry, immunofluorescence and scanning electron microscopy. Inhibition of tunneling nanotubes (TNTs) between glioblastoma cells and T cells was performed using carbenoxolone. Fluorogenic probes were used for mitochondrial membrane potential and reactive oxygen species (ROS) in mitochondria, glioblastoma cells and T cells after co-culture. Viability and LAG-3 levels were analyzed in T cells.</p><p><strong>Results: </strong>Glioblastoma cells show connections between themselves and forms physical connections with T cells through TNTs. Glioblastoma cells hijack mitochondria from T cells through these connections and effect was reversed on using carbenoxolone. Glioblastoma cells show increased mitochondrial membrane potential and decreased mitochondrial ROS after co-culture, while ROS was increased in glioblastoma cells and decreased in T cells.</p><p><strong>Conclusion: </strong>We show for the first time that glioblastoma cells and T cells physically connect through TNTs. Most importantly, glioblastoma cells hijack the mitochondria of T cells for its own advantage. By focusing on these complex tumor-immune cell interactions, this study aims to uncover a novel mode of physical communication in glioblastoma microenvironment.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-NOTA-NFB PET/MRI in glioma recurrence: comparison with ¹¹C-methionine PET/MRI and contrast-enhanced MRI.","authors":"Zhenwei Du, Yi Luo, Jinju Sun, He Long, Jianping You, Xin Li, Lunshan Xu, Weiguo Zhang, Xiao Chen","doi":"10.1007/s11060-025-05159-x","DOIUrl":"https://doi.org/10.1007/s11060-025-05159-x","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the clinical utility of ¹⁸F-NOTA-NFB PET/MRI relative to ¹¹C-methionine (¹¹C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection.</p><p><strong>Methods: </strong>Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired ¹⁸F-NOTA-NFB and ¹¹C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via ¹⁸F-NOTA-NFB and ¹¹C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of ¹⁸F-NOTA-NFB and ¹¹C-MET SUVmax/TBR was tested by receiver operating characteristic curve.</p><p><strong>Results: </strong>Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of ¹⁸F-NOTA-NFB PET were equivalent to ¹¹C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, ¹⁸F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of ¹¹C-MET (P < 0.001). Although ¹¹C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to ¹¹C-MET TBR (AUC = 0.889, P = 0.75), ¹⁸F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and ¹⁸F-NOTA-NFB TBR (AUC = 0.829, P = 0.42).</p><p><strong>Conclusion: </strong>The diagnostic efficacy of ¹⁸F-NOTA-NFB PET or PET/MRI performed equivalent to ¹¹C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to ¹¹C-MET, ¹⁸F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SIN1 facilitates glioma progression and is associated with the KRAS/ERK pathway.","authors":"Haowei Cao, Zhihan Yan, Mengwei Li, Jing Wang, Haihan Zhang, Yu Cheng, Jinmin Sun, Jing Ren, Dejun Yang","doi":"10.1007/s11060-025-05166-y","DOIUrl":"https://doi.org/10.1007/s11060-025-05166-y","url":null,"abstract":"<p><strong>Purpose: </strong>Glioma is the most common primary brain and spinal cord tumor, with effective treatments still lacking. Stress-activated protein kinase-interacting protein 1 (SIN1) has been reported to be upregulated in various tumor types, contributing to tumorigenesis. However, its specific role in glioma remains unclear. This study aimed to investigate SIN1's expression, clinical significance, biological functions, and underlying molecular mechanisms in glioma.</p><p><strong>Methods: </strong>SIN1 expression and its association with clinicopathological features and prognosis were analyzed using data from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA). SIN1 levels were quantified in glioma tissues and cell lines. The functional roles of SIN1 were evaluated by silencing or overexpressing it in glioma cells. RNA sequencing was used to identify downstream pathways, which were further validated through in vitro experiments. Additionally, the relationship between SIN1 and immune cell infiltration was investigated.</p><p><strong>Results: </strong>SIN1 is aberrantly upregulated in glioma, significantly correlating with adverse clinicopathological features and poor patient prognosis. Functional studies reveal that SIN1 upregulation enhances glioma cell proliferation and migration while suppressing apoptosis. Mechanistically, SIN1 exerts its oncogenic effects might be through the KRAS4A/ERK pathway. Furthermore, SIN1 expression is associated with altered immune cell infiltration within the tumor microenvironment.</p><p><strong>Conclusion: </strong>This study identifies SIN1 as a critical oncoprotein in glioma, upregulated in tumors and associated with aggressive features and poor survival. It drives tumor progression by enhancing proliferation/migration and suppressing apoptosis might via the KRAS4A/ERK pathway, while potentially modulating immune infiltration. These findings highlight SIN1's promise as a novel therapeutic target.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary habits in relation to outcome and therapy-related toxicity in patients with glioblastoma - a retrospective cohort study.","authors":"Tareq M Haedenkamp, Linda Götz, Tananeh Ansafi, Michael Gerken, Monika Klinkhammer-Schalke, Anna Fischl, Markus J Riemenschneider, Julia Maurer, Martin Proescholdt, Oliver Kölbl, Nils Ole Schmidt, Ralf Linker, Elisabeth Bumes, Peter Hau","doi":"10.1007/s11060-025-05137-3","DOIUrl":"https://doi.org/10.1007/s11060-025-05137-3","url":null,"abstract":"","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemagglutinating virus of Japan envelope encapsulating microRNA-34a-5p robustly induces apoptosis of malignant meningioma cells by suppressing survivin.","authors":"Takaaki Ishikawa, Masahide Matsuda, Yasufumi Kaneda, Eiichi Ishikawa","doi":"10.1007/s11060-025-05172-0","DOIUrl":"https://doi.org/10.1007/s11060-025-05172-0","url":null,"abstract":"<p><strong>Purpose: </strong>Malignant meningiomas are characterized by high recurrence rates and limited therapeutic options beyond surgery and radiation. This study aimed to develop a novel nucleic acid-based therapeutic approach for malignant meningiomas and to evaluate its efficacy both in vitro and in vivo.</p><p><strong>Methods: </strong>IOMM-Lee and HKBMM cell lines were used as models of malignant meningioma. Inhibitory effects of hemagglutinating virus of Japan envelope (HVJ-E) and microRNA-34a-5p (miR-34a-5p) were assessed using cell viability assays, apoptosis assays, RT-qPCR, and western blotting. Finally, the tumor suppressive effect of HVJ-E encapsulating miR-34a-5p was evaluated using a subcutaneous xenograft model in nude mice.</p><p><strong>Result: </strong>HVJ-E significantly reduced viability of malignant meningioma cells. Furthermore, HVJ-E encapsulating miR-34a-5p demonstrated enhanced anti-tumor activity by inducing apoptosis through downregulation of survivin expression. This tumor-suppressive effect was also confirmed in a subcutaneous mouse model.</p><p><strong>Conclusion: </strong>Our findings indicate that HVJ-E encapsulating miR-34a-5p effectively inhibits the growth of malignant meningioma cells both in vitro and in vivo. This novel combination therapy holds promise as a potential treatment strategy for malignant meningiomas.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}